The University of Colorado Cancer Center is a """"""""Center"""""""" within the organizational structure of the School of Medicine at the University of Colorado Health Sciences Center campus. The major goals of the Cancer Center are: 1) to contribute through a coordinated research, clinical treatement, control, and educational effort to the eventual elimination of cancer as a human health problem; and 2) to provide the citizens of the State of Colorado and the Rocky Mountain Region with state-of-the-art cancer therapy, research, control and educational programs. The Rocky Mountain Region and its approximate 5 million inhabitants is the largest region of the U.S. not served by an NCI funded Cancer Center. The members of the University of Colorado Cancer Center currently have more than $18 million in outside grant and contract support, and provide the major clinical care for over 30% of the cancer patients in this region. We provide the primary access to clinical studies for patients in this region. As our cancer efforts have intensified over the past 2-3 years our needs for interdisciplinary coordination, space, and new personnel have increased markedly. The support of this core support grant and institutional support should aid us in establishing a true center of excellence in cancer. The Cancer Center has 4 major program areas; basic research, clinical activities, cancer control activities, and educational activities each with an Associate Director. The Basic Science and Clinical Programs are subdivided into smaller program areas. These include Immunology, Molecular Biology, Hormones, Growth Regulation, Cell Surface, and Chromosomes for the Basic Science Program and Medical, Surgical, Radiation, Pediatric and Nursing Oncology for the Clinical Program. The primary planning and management decisions are made by the Management Committee which consists of the Director, Associate Directors and Program Leaders. There are 9 shared core facilities which provide support for the research efforts of Center members. The Center has a number of affiliated Schools, Hospitals and Institutes who are represented on the Cancer Center Board, an Advisory Board which reports to the Dean and Director. This Board assures the coordination of all the institutions in the region which are committed to the control of the cancer problem. Thus, the University of Colorado Cancer Center provides the leadership for the interdisciplinary study of cancer in the Rocky Mountain Region.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046934-02
Application #
3101848
Study Section
Cancer Center Support Grant Review Committee (CCS)
Project Start
1988-03-01
Project End
1991-02-28
Budget Start
1989-03-01
Budget End
1990-02-28
Support Year
2
Fiscal Year
1989
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Type
Schools of Medicine
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Tuttle, Kathryn D; Krovi, S Harsha; Zhang, Jingjing et al. (2018) TCR signal strength controls thymic differentiation of iNKT cell subsets. Nat Commun 9:2650
Keysar, Stephen B; Eagles, Justin R; Miller, Bettina et al. (2018) Salivary Gland Cancer Patient-Derived Xenografts Enable Characterization of Cancer Stem Cells and New Gene Events Associated with Tumor Progression. Clin Cancer Res 24:2935-2943
Salmon, Loïc; Stull, Frederick; Sayle, Sabrina et al. (2018) The Mechanism of HdeA Unfolding and Chaperone Activation. J Mol Biol 430:33-40
Kleczko, Emily K; Heasley, Lynn E (2018) Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities. Mol Cancer 17:60
Steckelberg, Anna-Lena; Akiyama, Benjamin M; Costantino, David A et al. (2018) A folded viral noncoding RNA blocks host cell exoribonucleases through a conformationally dynamic RNA structure. Proc Natl Acad Sci U S A 115:6404-6409
Pilling, Amanda B; Kim, Jihye; Estrada-Bernal, Adriana et al. (2018) ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer. Oncotarget 9:8823-8835
Antonioli, Alexandra H; White, Janice; Crawford, Frances et al. (2018) Modulation of the Alternative Pathway of Complement by Murine Factor H-Related Proteins. J Immunol 200:316-326
Boswell, Zachary K; Rahman, Samiur; Canny, Marella D et al. (2018) A dynamic allosteric pathway underlies Rad50 ABC ATPase function in DNA repair. Sci Rep 8:1639
Fitzwalter, Brent E; Towers, Christina G; Sullivan, Kelly D et al. (2018) Autophagy Inhibition Mediates Apoptosis Sensitization in Cancer Therapy by Relieving FOXO3a Turnover. Dev Cell 44:555-565.e3
Duex, Jason E; Swain, Kalin E; Dancik, Garrett M et al. (2018) Functional Impact of Chromatin Remodeling Gene Mutations and Predictive Signature for Therapeutic Response in Bladder Cancer. Mol Cancer Res 16:69-77

Showing the most recent 10 out of 1634 publications